PIK3CA and non-small cell lung carcinoma: PIK3CA mutant NSCLC patients exhibited similar response to EGFR-TKIs compared with wild-type patients with corresponding pooled OR of 0.70 (95% CI, 0.22-2.18) (Figure 5A).